Inclusion of Subjects who are Obese in Drug Development: Current Status and Opportunities

The prevalence of obesity has grown tremendously in recent years and this population has an increased risk of disease comorbidities. The presence of disease comorbidities requires treatment interventions and proper dosing guidelines. However, drug development programs often do not have adequate repr...

Celý popis

Podrobná bibliografie

Vydáno v:	Journal of clinical pharmacology Ročník 63; číslo S2; s. S10 - S17
Hlavní autoři:	Vaidyanathan, Jayabharathi, Fletcher, Elimika Pfuma, Ramamoorthy, Anuradha, Madabushi, Rajanikanth, Burckart, Gilbert J.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Rockville Wiley Subscription Services, Inc 01.11.2023
Témata:	Clinical trials Comorbidity Dosage Drug development Drug dosages Obesity Patients Pediatrics Risk assessment
ISSN:	0091-2700, 1552-4604, 1552-4604
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!